Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Welcome to the Jundishapur Journal of Microbiology, a peer-reviewed publication dedicated to advancing the field of microbiology. Published by BRIEFLAND, this journal focuses on key areas such as infectious diseases and medical microbiology, offering a platform for researchers to share their findings from 2009 to 2024. Despite its current positioning in Quartile 4 across various categories in 2023, the journal provides a valuable resource for budding scientists and established professionals alike, contributing to the growing body of knowledge in these critical areas. While it is not an open-access journal, the Jundishapur Journal prioritizes the dissemination of research in the Netherlands, facilitating a deeper understanding of microbial science and its implications for public health. Join a community of innovators committed to exploring both emerging and established themes in microbiology.

Antimicrobial Resistance and Infection Control is a leading open access journal published by BMC, dedicated to the dissemination of research in the critical area of antimicrobial resistance and its impact on infection control practices. Since its inception in 2012, the journal has quickly established itself as a vital resource for researchers, healthcare professionals, and policymakers, featuring a robust array of studies that address the escalating threats posed by antimicrobial resistance across various contexts. With its impressive Q1 rankings across multiple categories—including Infectious Diseases, Microbiology, Pharmacology, and Public Health—the journal’s influence is underscored by its consistent placement in the upper echelons of academic research. Furthermore, it holds commendable ranks in Scopus, with percentiles placing it in the top tier of its respective fields. The journal serves as an essential platform for innovative research and discussions aimed at curbing the threats of antimicrobial resistance, thereby supporting the global health community in striving for effective solutions to safeguard public health.

Indian Journal of Medical Microbiology, published by Elsevier, is a pivotal peer-reviewed journal dedicated to the field of medical microbiology, providing a vital platform for research and scholarship since its inception in 1986. With an Open Access model established in 2001, it ensures the dissemination of scientific knowledge to a global audience, enhancing accessibility for researchers, professionals, and students alike. The journal's scope spans critical areas including immunology, infectious diseases, and microbiology, with an impressive trajectory marked by converged years of publication allowing for a comprehensive exploration of evolving scientific trends. As of 2023, the journal holds a Q3 ranking in Infectious Diseases and Microbiology (medical) and a Q4 ranking in Immunology and Microbiology categories, reflecting its significant yet growing impact in the field. Researchers seeking to contribute to or stay updated on the latest advancements in medical microbiology will find the Indian Journal of Medical Microbiology a valuable resource, as it consistently bridges the gap between emerging science and clinical application.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.